Alexion Pharmaceuticals (NASDAQ:ALXN) continues its winning streak this month as the No. 1 Top 5 stock on my buy list. In early December, the company enjoyed a major windfall as European Union regulators approved a new use for Soliris, the company’s only approved drug. Soliris will now treat atypical Hemolytic-uremic syndrome, a severe blood disorder that became an epidemic in Germany in May 2011. This treatment, which will launch in the first half of the new year, will be a boon to the company because Alexion gets the benefit of a new customer base with relatively minor up-front costs.
Also, the company is headed toward another stunning earnings announcement on Feb. 6. Analysts currently expect Alexion to grow sales by 41.7% and earnings by 30.8%. In addition, the analyst community has revised its earnings-per-share estimates 13% higher in the past three months, which suggests another hefty earnings surprise for Q4 2011.